Tema Etfs LLC Decreases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Tema Etfs LLC has reduced its stake in Alnylam Pharmaceuticals by 60.3%, selling 9,848 shares and holding a total of 6,475 shares valued at approximately $1,748,000.
• Alnylam Pharmaceuticals reported $0.32 earnings per share for the last quarter, exceeding expectations by $0.86, with a year-over-year revenue increase of 17.3%.
• Over 92.97% of Alnylam's stock is owned by institutional investors, with numerous firms recently increasing their holdings significantly.

Tema Etfs LLC lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 60.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,475 shares of the biopharmaceutical company's stock after selling 9,848 shares during the period. Tema Etfs LLC's holdings in Alnylam Pharmaceuticals were worth $1,748,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ALNY. SVB Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at about $27,000. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $28,000. Whipplewood Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the last quarter. Bessemer Group Inc. grew its position in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares during the period. Finally, Colonial Trust Co SC bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $35,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ALNY. Truist Financial began coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $385.00 price target for the company. Wells Fargo & Company increased their price target on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. JPMorgan Chase & Co. increased their price target on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Barclays increased their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Finally, Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $405.33.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,979 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the transaction, the chief executive officer directly owned 56,221 shares of the company's stock, valued at approximately $25,483,292.67. This trade represents a 11.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,396 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $632,764.92. Following the transaction, the executive vice president directly owned 22,719 shares in the company, valued at $10,297,841.13. This trade represents a 5.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,594 shares of company stock valued at $25,551,456 over the last three months. Corporate insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock traded down $5.82 on Monday, reaching $446.51. The stock had a trading volume of 827,614 shares, compared to its average volume of 1,190,821. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $469.81. The company has a market cap of $58.53 billion, a P/E ratio of -180.77 and a beta of 0.32. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The business's 50 day moving average is $374.57 and its two-hundred day moving average is $303.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The firm had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company's revenue for the quarter was up 17.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.